Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

72 Annual Financial Statement Konzern-Jahresabschluss
Notes to the consolidated financial statements for the fiscal
year from 1 July 2009 to 30 June 2010
1. General Information
biolitec AG and its subsidiaries produce and sell medical laser devices, drugs and disposables and are
specialized in the field of medical research and development.
biolitec AG, Jena, was founded on March 17, 1999 (deed roll no. 0257/1999 of German notary Herbert
Freiherr von Schlotheim-Reinbrecht, Jena) with a capital stock of EUR 50,000. It is a stock corporation
(Aktiengesellschaft) according to German Law. The parent company’s registered seat is: Otto-Schott-
Straße 15, 07745 Jena (Germany).
After the increase in capital against non-cash contributions in the scope of the contribution and post
formation agreement dated 12 September 2000, on the subject of the interests held by BioMed Technology
Holdings Ltd., Labuan / Malaysia (“BioMed“) in corporations, biolitec was for the first time obligated
to prepare consolidated financial statements. The first set of consolidated financial statements
was prepared as of June 30, 2001. June 30, is also the balance sheet date of all consolidated subsidiaries
and second-tier subsidiaries, except for AndaOptec Ltd., Livani/ Latvia and biolitec Private India Ltd.,
Bangalore/India (March 31). AndaOptec Ltd. prepares an interim financial statement with due date June
30, and biolitec Private India Ltd., is included in the group’s financial statements in accordance with IAS
27.27.
On 13 November 2000, the shares of biolitec AG were admitted to the ‘Geregelter Markt’ and to trading
on the ‘Neuer Markt’ of the Frankfurt/Main Stock Exchange. In the course of the new segmentation of
the German stock market, biolitec AG received the approval for Prime Standard on 15 January 2003.
The consolidated financial statement is presented in Euro.
2. Activities of the biolitec group
Biolitec is the technology leader in diode lasers, fiber-optical consumables and photo-dynamic active
substances. It is the sole supplier for photodynamic therapy owning all relevant core competences
(photosensitizer, laser, optical fibers and the approved cancer drug Foscan). This combination of medical
technology and agent development for different medical indications distinguishes biolitec.
The company operates in two domestic as well as numerous foreign locations. 75% of turnover is generated
in Europe and the USA by producing and selling medical lasers, laser probes and optical fibers.